AA
CRVS icon

Ancora Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Ancora Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$847K Buy
56,723
+1,955
+4% +$27.1K 0.02% 451
2026
Q1 		$801K Buy
54,768
+7,101
+15% +$113K 0.02% 444
2025
Q4 		$367K Buy
47,667
+377
+0.8% +$2.97K 0.01% 606
2025
Q3 		$349K Buy
47,290
+4,183
+10% +$21.4K 0.01% 612
2025
Q2 		$172K Buy
43,107
+5,238
+14% +$19.1K ﹤0.01% 755
2025
Q1 		$120K Hold
37,869
– – ﹤0.01% 819
2024
Q4 		$203K Buy
37,869
+14,584
+63% +$109K ﹤0.01% 706
2024
Q3 		$123K Buy
+23,285
New +$83.6K ﹤0.01% 784

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ancora Advisors's CRVS Position: Q2 2026 in Review

Ancora Advisors increased its Corvus Pharmaceuticals (CRVS) stake by 3.6% in Q2 2026, buying an estimated $27.1K and bringing the position to 56,723 shares worth $847K. The position accounts for 0.02% of the portfolio, ranked #451.

Ancora Advisors first reported a position in CRVS in Q3 2024 and has held it in 8 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Ancora Advisors held 56,723 shares of Corvus Pharmaceuticals worth $847K as of Q2 2026.
  • Ancora Advisors bought 1,955 Corvus Pharmaceuticals shares in Q2 2026, an estimated $27.1K.
  • Corvus Pharmaceuticals made up 0.02% of Ancora Advisors's portfolio in Q2 2026, its #451 holding.
  • Ancora Advisors first reported a position in Corvus Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.